Literature DB >> 26493815

Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates.

Monika M Schoels1, Daniel Aletaha2, Josef S Smolen2.   

Abstract

Keywords:  Outcomes research; Psoriatic Arthritis; Treatment

Mesh：

Year:  2015        PMID： 26493815     DOI： 10.1136/annrheumdis-2015-208521

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast.

Authors:  V Venerito; D Natuzzi; R Bizzoca; N Lacarpia; F Cacciapaglia; G Lopalco; F Iannone
Journal:  Clin Exp Immunol       Date:  2020-05-27       Impact factor: 4.330

2.  Cardiovascular risk reclassification according to six cardiovascular risk algorithms and carotid ultrasound in psoriatic arthritis patients.

Authors:  Dionicio A Galarza-Delgado; Jose R Azpiri-Lopez; Iris J Colunga-Pedraza; Natalia Guajardo-Jauregui; Alejandra B Rodriguez-Romero; Salvador Lugo-Perez; Jesus A Cardenas-de la Garza; Rosa I Arvizu-Rivera; Diana E Flores-Alvarado; Octavio Ilizaliturri-Guerra; Gisela Garcia-Arellano; Andrea C Garza-Acosta
Journal:  Clin Rheumatol       Date:  2021-11-26       Impact factor: 2.980

3.  DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.

Authors:  Silva Pukšić; Pernille Bolton-King; Joseph Sexton; Brigitte Michelsen; Tore K Kvien; Hilde Berner Hammer
Journal:  RMD Open       Date:  2018-11-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.